Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors-Reference-Cited by-同舟云学术

Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

Published:2018-07-15 Issue:3 Volume:50 Page:835-842
ISSN:1598-2998
Container-title:Cancer Research and Treatment
language:en
Short-container-title:Cancer Res Treat

Author:

Kim Tae Min,Lee Keun-Wook,Oh Do-Youn,Lee Jong-Seok,Im Seock-Ah,Kim Dong-Wan,Han Sae-Won,Kim Yu Jung,Kim Tae-You,Kim Jee Hyun,Han Hyesun,Kim Woo Ho,Bang Yung-Jue

Publisher

Korean Cancer Association

Subject

Cancer Research,Oncology

Link

http://e-crt.org/upload/pdf/crt-2017-303.pdf

Reference14 articles.

1. ERBB receptors and cancer: the complexity of targeted inhibitors

2. The quest to overcome resistance to EGFR-targeted therapies in cancer

3. Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer

4. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

5. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HER2-targeted therapies beyond breast cancer — an update;Nature Reviews Clinical Oncology;2024-07-22

2. Overcoming brain-derived therapeutic resistance in HER2+ breast cancer brain metastasis;2024-02-22

3. Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens;Breast Cancer Research and Treatment;2024-01-23

4. Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion;Journal of Thoracic Oncology;2024-01

5. Novel HER-2 Targeted Therapies in Breast Cancer;Cancers;2023-12-23